Sismondo, S. (2007). Ghostmanagement: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine, 4, 1429-1433. Retrieved from www.plos.org on June 8, 2008.
Sismondo, S. (2008a). How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science & Medicine, 66, 1909-1914. Sismondo, S. (2008b). Pharmaceutical company funding and its consequences: A qualitative systematic review. Contemporary Clinical Trials, 29, 109-113. Tierney, W. M., & Gerrity, M. S. (2005). Scientific discourse, corporate ghostwriting, journal policy and public trust. Journal of General Internal Medicine, 20, 550-551. Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal, 326, 1171-1173. Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical insustry: Review of studies in new drug applications. British Medical Journal, 326. Retrieved from www.bmj.com on June 9, 2008. Moffatt, B., & Elliott, C. (2007). Ghostmarketing: Pharmaceutical companies and ghostwritten journal articles. Perspectives in Biology and Medicine, 50, 18-31. Campbell, E. G., Weissman, J. S., Shringhaus, S., Rao, S. R., Moy, B., et al. (2007). Institutional academic-industry relationships. JAMA, 298, 1779-1786. Bero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007). Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. PLoS Medicine, 4. Retrieved from www.plosmedicine.org on June 7, 2008. Healy, D., & Cattell, D. (2003). Interface between authorship, industry, and science in the domain of therapeutics. British Journal of Psychiatry, 183, 22-27. Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., et al. (2006). Why olanzapne beats risperidone, risperidone, beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of heat-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry, 163, 1645. --- To make changes to your subscription contact: Bill Southerly ([EMAIL PROTECTED])
